ES2194937T3 - Compuestos ciclicos, su produccion y uso como antagonistas de los receptores de taquiquinina. - Google Patents

Compuestos ciclicos, su produccion y uso como antagonistas de los receptores de taquiquinina.

Info

Publication number
ES2194937T3
ES2194937T3 ES96104500T ES96104500T ES2194937T3 ES 2194937 T3 ES2194937 T3 ES 2194937T3 ES 96104500 T ES96104500 T ES 96104500T ES 96104500 T ES96104500 T ES 96104500T ES 2194937 T3 ES2194937 T3 ES 2194937T3
Authority
ES
Spain
Prior art keywords
ring
optionally replaced
taquiquinine
production
heterociclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96104500T
Other languages
English (en)
Inventor
Hideaki Natsugari
Takenori Ishimaru
Takayuki Doi
Yoshinori Ikeura
Chiharu Kimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ES2194937T3 publication Critical patent/ES2194937T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

NUEVOS COMPUESTOS DE LA SIGUIENTE FORMULA GENERAL O SALES DE LOS MISMOS EN DONDE EL ANILLO M ES UN ANILLO HETEROCICLICO CON - N = C <, CO - N < O - CS -N < COMO LA ESTRUCTURA PARCIAL -X Y<; R{SUP,A} Y R{SUP,B} ESTAN UNIDOS ENTRE SI PARA FORMAR UN ANILLO A, O SON IGUALES O DIFERENTES Y REPRESENTAN, INDEPENDIENTEMENTE, UN ATOMO DE HIDROGENO O UN SUSTITUYENTE EN EL ANILLO M; EL ANILLO A Y EL ANILLO B REPRESENTAN, INDEPENDIENTEMENTE, UN ANILLO HOMOCICLICO O HETEROCICLICO OPCIONALMENTE SUSTITUIDO, Y AL MENOS UNO DE ELLOS ES UN ANILLO HETEROCICLICO OPCIONALMENTE SUSTITUIDO; EL ANILLO C ES UN ANILLO HOMOCICLICO O HETEROCICLICO OPCIONALMENTE SUSTITUIDO; EL ANILLO Z ES UN ANILLO OPCIONALMENTE SUSTITUIDO; Y N REPRESENTA UN ENTERO DE DESDE 1 A 6, O UNA SAL DEL MISMO, QUE TIENE UN EXCELENTE EFECTO ANTAGONISTA DEL RECEPTOR DE TAQUIQUININA, Y SU PRODUCCION, Y COMPOSICIONES FARMACEUTICAS.
ES96104500T 1995-03-24 1996-03-21 Compuestos ciclicos, su produccion y uso como antagonistas de los receptores de taquiquinina. Expired - Lifetime ES2194937T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP9143695 1995-03-24
JP20755395 1995-07-20
JP26472795 1995-09-18
JP3003396 1996-01-23

Publications (1)

Publication Number Publication Date
ES2194937T3 true ES2194937T3 (es) 2003-12-01

Family

ID=27459171

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96104500T Expired - Lifetime ES2194937T3 (es) 1995-03-24 1996-03-21 Compuestos ciclicos, su produccion y uso como antagonistas de los receptores de taquiquinina.

Country Status (17)

Country Link
US (3) US5786352A (es)
EP (1) EP0733632B1 (es)
KR (1) KR960034203A (es)
CN (1) CN1140172A (es)
AR (1) AR003937A1 (es)
AT (1) ATE242243T1 (es)
AU (1) AU699611B2 (es)
BR (1) BR9601125A (es)
CA (1) CA2172421A1 (es)
DE (1) DE69628484T2 (es)
ES (1) ES2194937T3 (es)
HU (1) HUP9600732A3 (es)
IL (1) IL117631A (es)
MX (1) MX9601072A (es)
NO (1) NO309272B1 (es)
NZ (1) NZ286256A (es)
TW (1) TW394773B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
AR018772A1 (es) * 1998-03-19 2001-12-12 Takeda Chemical Industries Ltd Composicion farmaceutica para prevenir o tratar depresion, inquietud, enfermedad maniaca depresiva o psicopatia, compuesto heterociclico comprendido en lamisma, prodroga obtenida a partir del anterior, metodo para producir dicho compuesto y su uso
AU5305299A (en) * 1998-08-26 2000-03-21 Tanabe Seiyaku Co., Ltd. Naphthyridine derivatives and process for the preparation thereof
WO2000032192A1 (en) * 1998-11-27 2000-06-08 Takeda Chemical Industries, Ltd. Drugs
SI1157005T1 (en) * 1999-02-24 2005-02-28 F. Hoffmann-La Roche Ag 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
EP1394150B1 (en) 1999-02-24 2011-01-19 F. Hoffmann-La Roche AG 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
MXPA02004330A (es) 1999-11-03 2004-07-30 Albany Molecular Res Inc Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
PT1103545E (pt) * 1999-11-29 2004-03-31 Hoffmann La Roche 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida
KR100821410B1 (ko) 2000-07-11 2008-04-10 에이엠알 테크놀로지, 인크. 4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
US20040023843A1 (en) * 2000-09-26 2004-02-05 Takayuki Doi Preventives/remedies for emotional disorders
CA2432543A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Combination drugs
IL158941A0 (en) 2001-05-22 2004-05-12 Neurogen Corp Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
WO2003029254A1 (en) * 2001-09-28 2003-04-10 Takeda Chemical Industries, Ltd. Process for preparation of tricyclic compounds
EP1457493A4 (en) * 2001-12-10 2005-11-30 Kyorin Seiyaku Kk CONDENSED, BICYCLIC PYRIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS
ATE427310T1 (de) * 2002-01-18 2009-04-15 Kyorin Seiyaku Kk Kondensierte bicyclische pyrimidinderivate
KR20040099367A (ko) * 2002-03-26 2004-11-26 교린 세이야꾸 가부시키 가이샤 타키키닌 수용체 길항제로서의 축합 바이사이클릭 피리딘 유도체
US7625887B2 (en) 2003-01-28 2009-12-01 Takeda Pharmaceutical Company Limited Receptor agonists
TWI280239B (en) 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
US20050113365A1 (en) * 2003-11-10 2005-05-26 Sir Isaac Newton Enterprises Llc Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome
US20070142367A1 (en) * 2003-11-10 2007-06-21 Lundeen James E Method and medicine for treating gastrointestinal disorder including fecal incontinence
US20060148781A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating gastrointestinal disorder in a non-human mammal
US20060148782A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both
US20060148783A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating gastrointestinal disorder including fecal incontinence
UA91341C2 (ru) 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
UA95454C2 (uk) 2005-07-15 2011-08-10 Амр Текнолоджи, Інк. Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну
DE602006011485D1 (de) 2005-09-23 2010-02-11 Hoffmann La Roche Neue dosierformulierung
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AR064777A1 (es) 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US20110136788A1 (en) * 2008-08-07 2011-06-09 Minoru Maruyama Therapeutic agent for irritable bowel syndrome
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
AU2010247763B2 (en) 2009-05-12 2015-12-24 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
US8859776B2 (en) 2009-10-14 2014-10-14 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2691393B1 (en) 2011-03-31 2016-09-14 Pfizer Inc Novel bicyclic pyridinones
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
ME02925B (me) 2012-11-28 2018-04-20 Merck Sharp & Dohme Kompozicije i postupci za liječenje kancera
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3102576B8 (en) 2014-02-03 2019-06-19 Vitae Pharmaceuticals, LLC Dihydropyrrolopyridine inhibitors of ror-gamma
PT3207043T (pt) 2014-10-14 2019-03-25 Vitae Pharmaceuticals Llc Inibidores de di-hidropirrolopiridina de ror-gama
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
MX368391B (es) 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
WO2017024018A1 (en) 2015-08-05 2017-02-09 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
US11008340B2 (en) 2015-11-20 2021-05-18 Vitae Pharmaceuticals, Llc Modulators of ROR-gamma
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
JP2020528904A (ja) 2017-07-24 2020-10-01 ヴァイティー ファーマシューティカルズ，エルエルシー ＲＯＲγの阻害剤
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033288A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2357253A1 (de) * 1973-11-16 1975-05-22 Thomae Gmbh Dr K Neue chinolinderivate
ES431307A1 (es) * 1973-11-16 1976-09-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevos derivados de quinoleina.
DE2617101A1 (de) * 1976-04-17 1977-11-17 Thomae Gmbh Dr K Neue naphthyridine
DE2638828A1 (de) * 1976-08-28 1978-03-09 Thomae Gmbh Dr K Neue thieno-pyridine
DE2722416A1 (de) * 1977-05-18 1978-11-30 Thomae Gmbh Dr K Neue thiazolo-pyridine
US4746657A (en) * 1987-07-13 1988-05-24 A. H. Robins Company, Incorporated Fused aromatic tetrahydroazepinones (and thiones)
TW241258B (es) * 1992-04-15 1995-02-21 Takeda Pharm Industry Co Ltd
EP0585913B1 (en) * 1992-09-04 1997-12-29 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
EP0634402A1 (en) * 1993-07-14 1995-01-18 Takeda Chemical Industries, Ltd. Isochinolinone derivatives, their production and use
TW263498B (es) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd

Also Published As

Publication number Publication date
AU699611B2 (en) 1998-12-10
EP0733632B1 (en) 2003-06-04
KR960034203A (ko) 1996-10-22
DE69628484D1 (de) 2003-07-10
IL117631A0 (en) 1996-07-23
US6147071A (en) 2000-11-14
DE69628484T2 (de) 2004-05-19
AR003937A1 (es) 1998-09-30
US6489315B1 (en) 2002-12-03
HUP9600732A3 (en) 2000-03-28
HUP9600732A2 (en) 1997-03-28
TW394773B (en) 2000-06-21
ATE242243T1 (de) 2003-06-15
IL117631A (en) 2000-11-21
BR9601125A (pt) 1998-01-06
US5786352A (en) 1998-07-28
CA2172421A1 (en) 1996-09-25
NO961160L (no) 1996-09-25
MX9601072A (es) 1997-03-29
NO961160D0 (no) 1996-03-21
AU4826196A (en) 1996-10-03
CN1140172A (zh) 1997-01-15
EP0733632A1 (en) 1996-09-25
NZ286256A (en) 1999-05-28
HU9600732D0 (en) 1996-05-28
NO309272B1 (no) 2001-01-08

Similar Documents

Publication Publication Date Title
ES2194937T3 (es) Compuestos ciclicos, su produccion y uso como antagonistas de los receptores de taquiquinina.
ES2053451T3 (es) Un procedimiento para la preparacion de un compuesto que tiene propiedades farmacologicas utiles.
CO4770964A1 (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos
MX9605128A (es) Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
ES2161231T3 (es) Compuestos heterociclicos como antagonistas de bradiquinina.
ES2113368T3 (es) Antagonistas de serotonina.
AR009938A1 (es) Nuevos derivados de arilglicinamida, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos
MX9305379A (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene.
ES2175350T3 (es) Compuestos triciclicos que tienen afinidad de union a receptores de melatonina, su produccion y uso.
MX9300842A (es) Antagonistas de endotelina de sulfonamida.
ES2158814A1 (es) Antagonistas iii del receptor ccr-3.
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
PA8439101A1 (es) Lactamas e imidas heterociclicas de aralquilo y aralquilideno
ES2059207T3 (es) Procedimiento para la preparacion de derivados del taxano, nuevos derivados obtenidos y composiciones farmaceuticas que les contienen.
ES2054872T3 (es) Nuevos derivados de acido bencimidazolin-2-oxo-1-carboxilico utiles como antagonistas de los receptores 5-ht.
ES2153907T3 (es) Compuestos espiro tetraciclicos, procedimiento para su preparacion y su uso como antagonistas del receptor 5ht1d.
MX9301129A (es) Nuevas ciclosporinas y composiciones farmaceuticas que las contienen.
ES2163407T3 (es) Derivados piperidinilos tiaciclicos.
AR006119A1 (es) Compuestos de quinoxalinadionas uso de los mismos para la fabricacion de un medicamento, compuestos de quinoxalinas para producirlos y procedimiento parala preparacion de los mismos
UY27851A1 (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
ES2139024T3 (es) Produccion de xilitol por recombinacion y huesped utilizado para este procedimiento.
MX9304424A (es) Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
ES2105069T3 (es) Procedimiento para preparar antagonistas del receptor de fibrinogeno.
AR028743A1 (es) DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA
MX9300602A (es) Analogos de fenilalanina de bombesina.